An observational study in Lung Cancer, sponsored by Shanghai Pulmonary Hospital, Shanghai, China. Status unknown. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by Shanghai Pulmonary Hospital, Shanghai, China · Observational
The precise diagnosis and treatment of lung cancer is not only a major national strategic need but also an urgent demand from the general public. The "three stages" of precise diagnosis and treatment of lung cancer include early diagnosis, effective treatment, and precise evaluation. Currently, invasive methods are mainly used in these three stages of clinical practice. The non-invasive molecular diagnosis of early-stage lung cancer and the molecular evaluation of treatment efficacy are critical core issues in lung cancer clinical diagnosis and treatment. In response to this problem, this project aims to use exhaled breath as a sample to develop a scientific instrument with independent intellectual property rights, which integrates early-stage diagnosis of lung cancer and evaluation of treatment efficacy. We will also conduct related application research to meet the needs of the public and contribute to the health of the entire population.
7,333 studies on the registry are indexed under Lung Neoplasms; 1,554 are open to participants now.
This study's planned enrollment of 500 is above the median of 190 across 1,547 observational studies indexed under Lung Neoplasms.
Browse Lung Neoplasms studies →Shanghai Pulmonary Hospital, Shanghai, China is the lead sponsor of 157 studies on the registry; 94 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Biopsy patients in Shanghai Pulmonary Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
OS
Time from randomization to death (from any cause)
Time frame: From date of diagnosis until the date of death from any cause, whichever came first, assessed up to 24 months
PFS
The time between the initiation of randomization and the occurrence (any aspect) of tumor progression or death (from any cause)
Time frame: From date of diagnosis until the date of first documented progression from any cause, whichever came first, assessed up to 24 months
ORR
Refers to the proportion of subjects whose tumors shrink by a certain amount and remain for a certain period of time, including those with CR+PR
Time frame: The proportion of patients who achieved a 30%(usual) reduction in tumor volume while maintaining the minimum required duration was calculated at month 24 of the study
DOR
Is the time from the first documented response (CR or PR) to the first documented disease progression or death, whichever occurs first
Time frame: The time from first diagnosis of CR or PR to diagnosis of PD was calculated at 24 months of study
No study locations are listed for this record.
Plan to share: No
Start is estimated for Nov 2023; primary completion for Oct 2024, 11 months later.
Of 578 non-industry observational studies under Lung Neoplasms, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 172. This study's planned 11 months is below that.
Counting every sponsor, half of 685 studies reached it within 56 months; a quarter within 29 and three quarters within 130.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai Pulmonary Hospital, Shanghai, China →